Find disease awareness content and relevant supporting materials
Bimzelx is approved in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma.
UCB announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for Bimezlx (bimekizumab) for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments.
Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: Results from two randomized, Phase 3 trials
Objective: To evaluate the efficacy of secukinumab in subjects with psoriasis and concomitant psoriatic arthritis (PsA) with respect to psoriasis symptoms and physical function, we conducted pre-specified subanalyses of the phase 3 FIXTURE and ERASURE trials.
Positive top-line rRsults for Bimzelx in second phase III BE COMPLETE study for psoriatic arthritis. -UCB
UCB has announced positive top-line results from the Phase III BE COMPLETE study which evaluated the efficacy and safety of Bimzelx (bimekizumab) in the treatment of adults with active psoriatic arthritis, who were inadequate responders or intolerant to anti-tumor necrosis factor-alpha (anti-TNF-?) therapy.
Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. Up to 40 % of patients with psoriasis will go on to develop PsA, usually within 5-10 years of cutaneous disease onset.
Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature
While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities.
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
Psoriasis is a systemic inflammatory disease associated with numerous comorbidities and a profound impact on patients' quality of life. While its complex immune pathogenesis is still not fully delineated, current evidence supports a fundamental role of the T-helper-17 (TH-17) pathway and its related interleukin-17 (IL-17) cytokine.